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Abstract
Background: Non-invasive ventilation (NIV) can increase exercise tolerance, reduce exercise induced desaturation
and improve the outcome of pulmonary rehabilitation in patients with chronic respiratory disease. It is not known
whether it can be applied to increase exercise capacity in patients admitted with non-hypercapnic acute
exacerbations of COPD (AECOPD). We investigated the acceptability and feasibility of using NIV for this purpose.
Methods: On a single occasion, patients admitted with an acute exacerbation of chronic respiratory disease who
were unable to cycle for five minutes at 20 watts attempted to cycle using NIV and their endurance time (Tlim) was
recorded. To determine feasibility of this approach in clinical practice patients admitted with AECOPD were
screened for participation in a trial of regular NIV assisted rehabilitation during their hospital admission.
Results: In 12 patients tested on a single occasion NIV increased Tlim from 184(65) seconds to 331(229) seconds (p
= 0.04) and patients desaturated less (median difference = 3.5%, p = 0.029). In the second study, 60 patients were
admitted to hospital during a three month period of whom only 18(30)% were eligible to participate and of these
patients, only four (7%) consented to participate.
Conclusion: NIV improves exercise tolerance in patients with acute exacerbations of chronic respiratory disease but
the applicability of this approach in routine clinical practice may be limited.
Trial registration: http://www.controlled-trials.com/ISRCTN35692743
Background
Exercise limitation is a cardinal feature of COPD which
is particularly marked in patients who require hospital
admission. It is directly related to skeletal muscle weak-
ness [1-3] and quadriceps weakness is associated with
increased mortality in COPD [4]. Patients with low phy-
sical activity levels are more likely to be admitted to
hospital [5] and exacerbations themselves lead to a dra-
matic reduction in physical activity [6] and health status
[7] which can be prolonged, reflected in reduced time
spent outdoors [8]. Activity limitation is also associated
with a greater likelihood of relapse after discharge fol-
lowing accident and emergency department attendance
[9].
Although muscle weakness is multifactorial, disuse is
likely to be the major reversible factor with loss of
strength most pronounced in the muscles of locomotion
[10]. In healthy older people 10 days bed rest produces
a 20% fall in quadriceps strength [11]. An acute fall in
strength has been noted in patients admitted with acute
exacerbations of COPD (AECOPD) [12-14] and decline
in fat free mass in COPD is associated with exacerbation
frequency [15].
Pulmonary rehabilitation is a well established thera-
peutic strategy for out-patients with COPD, improving
exercise capacity and quality of life as well as reducing
hospital admissions and health care costs [16-19]. Out-
patient pulmonary rehabilitation started within 10 days
of discharge following AECOPD has been shown to
improve exercise capacity, quality of life and readmis-
sion rate [20,21]. Benefit has also been seen in patients
undergoing a supervised exercise program in their own
homes. A six week program begun straight after
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discharge, with twice weekly visits, improved shuttle
walk distance, quadriceps strength and quality of life
compared to usual care with a trend towards fewer
exacerbations at three months [22].
There are also some data looking at in-patient pro-
grams for patients with AECOPD after they have recov-
ered sufficiently but before discharge [23,24]. In these
studies patients were enrolled four to seven days after
admission to hospital. The investigators found that
walking distance almost doubled in the intervention arm
whereas it did not change in the control group. The
benefits of this early rehabilitation in terms of exercise
capacity, breathlessness and quality of life were large
and appeared to be maintained with unsupervised home
exercise program suggesting that the benefits from pre-
venting or reversing acute deteriorations of muscle
strength are important and can be sustained relatively
easily [24].
There are data to suggest that non-invasive ventilation
(NIV) can be used to allow stable COPD patients with
ventilatory limitation to exercise at higher intensities
[25-33] and it has also been used to allow mobilisation
in patients on an intensive care unit [34]. One study
investigating the effect of NIV on exercise tolerance in
acute hypercapnic exacerbations of respiratory disease
[35] showed that NIV with oxygen entrained improved
six minute walk distance, with reduced dyspnoea and
improved SpO2 compared to oxygen alone. It is there-
fore possible that, as in stable disease, NIV could sup-
port rehabilitation during an acute episode, allowing
patients to exercise who would otherwise be too breath-
less and so prevent loss of muscle strength and func-
tional capacity.
We present the results of two studies. The aims of the
studies were: 1) to determine the effect of NIV on exer-
cise tolerance in patients admitted to a specialist
respiratory hospital with an acute exacerbation of
chronic respiratory disease on a single occasion and 2)
to investigate the feasibility of enrolling patients with
non-hypercapnic AECOPD into a trial of NIV assisted
rehabilitation.
Methods
The two arms of the study were carried out indepen-
dently, Study 1 looking at the effect of NIV on a single
occasion at Royal Brompton Hospital and Study 2, look-
ing at the feasibility of regular NIV assisted exercise at
Chelsea and Westminster Hospital. Ethical approval was
granted by the South West London Ethics committee
and written consent was given by all participants. The
initial intention was to pursue a randomised controlled
trial as registered at http://www.controlled-trials.com/
ISRCTN35692743 but only the results of initial feasibil-
ity studies are presented here.
Acute effect of NIV on exercise tolerance (Study 1)
Patients admitted to the Royal Brompton Hospital with
an acute deterioration of chronic lung disease (including
Cystic Fibrosis [CF], Bronchiectasis), who were judged
by the clinical physiotherapy team to have significantly
impaired exercise capacity and were not expected to be
able to cycle for five minutes, were invited to participate.
Patients were naive to NIV-assisted exercise but noctur-
nal NIV use was not an exclusion. Patients had to be
able to follow instructions and be able to use an exercise
bike. Patients were excluded if they were known to be
acidotic (pH < 7.35), febrile, or had a heart rate (HR) >
120 min-1, a systolic blood pressure < 100 mmHg or
were considered unsafe to exercise by the medical team.
Unassisted exercise
Patients were asked to cycle on an upright static bike
(Horizon Fitness BSC 400) at 20W at 40-60 RPM for up
to five minutes without ventilatory support. Oxygen was
entrained at the baseline level predetermined by the
clinical team responsible for the patient by assessing
oxygen requirements during mobilisation. This was not
adjusted during exercise. Patients received standardised
encouragement to try to continue for five minutes. HR,
O2 saturation and symptoms (Borg score for breathless-
ness and leg discomfort) were recorded. If patients felt
unable to cycle for five minutes (symptom limited) or
suffered significant desaturation (stopped by supervising
physiotherapist if they desaturated by more than 4%
from baseline and to less than 88%) whilst cycling they
went on to try NIV assisted exercise.
NIV assisted exercise
NIV was delivered using a NIPPY ST+ via a full face
mask in NIV naïve individuals. If patients were already
using NIV at night their own machine and interface was
used. If patients were unable to tolerate a full face mask
a mouthpiece was trialled. For those naive to NIV a
pressure support of 10 cmH2O was used as a baseline
with a PEEP of 5 cmH2O. Ventilator settings were
adjusted as necessary to allow for increased ventilatory
demands and to maximise patient comfort during exer-
cise. Oxygen was entrained at the baseline flow rate and
not adjusted during exercise. Patients then cycled for up
to 20 minutes on a static bike at 20 watts. For a small
number of patients workload was increased during NIV
assisted exercise as they found the low resistance
uncomfortable. This meant that for some individuals a
change in Tlim could be reported and in others a
change in total work done (watts × time).
Outcome measures
Total time cycled was recorded and SpO2 was moni-
tored throughout and recorded at one minute intervals.
Breathlessness and leg fatigue were measured using the
Borg score immediately post exercise. Participants were
asked to rate the acceptability of exercising with NIV
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using a visual analogue scale scored (0-10). Patient
remarks about the difference in ability to exercise were
also recorded.
Feasibility of NIV assisted rehabilitation (Study 2)
Patients admitted to Chelsea and Westminster hospital
with an AECOPD as per current UK guidelines [36]
were screened for eligibility for a trial to evaluate regular
NIV-assisted exercise while they were an inpatient. All
patients were treated with antibiotics and oral corticos-
teroids. To be included, patients had to be expected to
remain an in-patient for more than 24 hours, be
expected to survive the admission and be safe to exer-
cise according to the criteria in the first part of the
study. If patients failed the latter criteria (heart rate,
blood pressure, fever or acidosis) they could be reas-
sessed on subsequent days. Where patients were eligible
the study was proposed to them by a member of the
clinical team and they were invited to participate. No
specific definition of exercise limitation was used as an
inclusion criterion, as this study was designed with the
knowledge that patients admitted to hospital with an
AECOPD become weaker whilst in hospital and because
patients who were not exercise-limited would be likely
to be managed as outpatients [12-14].
Statistical analysis
Data were analysed using SPSS. Descriptive data for
continuous variables with a normal distribution are pre-
sented as mean and standard deviation (SD) or median
and range for data not normally distributed. The paired
t test or the Wilcoxon signed rank test for non-para-
metric data and the chi squared test for categorical data
were used to identify any differences whilst exercising
with and without NIV. A significance level of < 0.05 was
used for all comparisons.
Results
Effect of NIV on exercise tolerance (Study 1)
Twenty-five patients were studied (Table 1). Eleven
(44%) patients had cystic fibrosis, 12 (48%) bronchiecta-
sis, one (4%) had primary ciliary dyskinesia and one
(4%) had obesity hypoventilation and dilated cardiomyo-
pathy. Forty-three per cent had had prior exposure to
NIV. Eight patients were able to cycle for five minutes
at 20W and therefore did not proceed to NIV-assisted
exercise. In 12 patients exercising with a fixed workload,
Tlim increased from 184(65) sec to 331(229) sec (p =
0.04) (Figure 1) (table 2). In five patients, workload was
increased whilst exercising on NIV so only total work
done is reported. In this subgroup median increase in
exercise time was 85 secs (30%) and median total work
done increased from 1560 (600-9720)J to 8336 (4800-
21960)J (p = 0.043). 10 patients used supplemental oxy-
gen at rest and during exercise (oxygen saturation values
in tables 1 and 2 reflect this). In all patients (n = 17)
work done increased from 5437 (600-21000)J to 9081
(1200-21960)J (p = 0.016) (Figure 2).
Change in total work done did not differ significantly
between those naïve to NIV and those using nocturnal
NIV with a mean change of 3263 (6028)J vs 4262 (3956)
J respectively (p = 0.7).
It took an estimated 15 minutes for most patients to
become familiarised with the mask and machine and to
optimise their ventilator settings at rest. Patients were
thus able to cycle with NIV with only a short introduc-
tion to the equipment. Patients comments were
recorded and were both positive and negative including
‘claustrophobic’ and ‘suffocating’ as well as ‘pleasant sen-
sation’, ‘felt mask made exercise easier, after cycling for
a while I appreciated having the oxygen’ and ‘my legs
didn’t hurt so much’. However, all patients who exer-
cised with NIV stated they would be prepared to repeat
the intervention even though some (35%) scored five or
more on the visual analogue scale for discomfort with a
mean score of 4.3 (3.3) range 0-10. No adverse events
associated with exercise occurred.
Feasibility of NIV assisted rehabilitation (Study 2)
Sixty patients admitted to Chelsea and Westminster
hospital between February and May 2011 with an acute
infective exacerbation of COPD were assessed for possi-
ble participation. Thirty-nine (65%) were male, mean
age was 72 (12) years. Median length of stay (LOS) was
Table 1 Patient characteristics for study 1
All patients Able to cycle > 5 minutes at 20W unassisted Unable to cycle > 5 minutes at 20W unassisted p
n (%male) 25 (58%) 8(88%) 17(44%) 0.08‡
Age (yrs) 48.0 (18.8) 42.9 (12.2) 50.6 (21.3) 0.35*
FEV1 (L) 0.84(0.49-2.85) 0.97 (0.68-2.85) 0.69 (0.49-1.40) 0.03
†
FVC(L) 1.74 (0.80-4.55) 1.89 (1.06-4.55) 1.54 (0.80-2.31) 0.13†
Resting SpO2 94.9 (3.0) 96.0 (2.7) 94.4 (3.1) 0.21*
Resting HR 97.5 (15.1) 96.8 (12.1) 97.8 (16.3) 0.87*
Data are presented as mean (SD) or median (range)
* unpaired t test, † Wilcoxon signed rank test, ‡ Chi squared
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3 (0 to 19) days with 32% patients being discharged
within 48 hours. Table 3 shows outcome of screening
for eligibility.
Forty-two (70%) patients did not meet the eligibility
criteria, the most common reasons being that they were
only expected to have a short admission or were too
unwell to exercise. Of those not fit to exercise, nine
patients (56%) had a musculoskeletal problem including
severe osteoarthritis of the hip, rheumatoid arthritis and
a new Colles’ fracture. Other reasons included dementia
(13%) or neurological problems (13%). Of those consid-
ered eligible the majority 10/18 (56%) declined to parti-
cipate and four were excluded for logistical reasons. Of
those declining two patients did not wish to take part in
research but most (70%) either did not feel they could
exercise or did not want to exercise.
Of the four patients who agreed to participate it
became apparent during the assessment process that
one was too frail to continue (physiotherapist’s assess-
ment). One patient withdrew after the first exercise ses-
sion as he found exercise too distressing due to severe
breathlessness. Two patients continued NIV assisted
exercise to discharge from acute care, however, of these
one received only one exercise session and the other
only two, due to short length of stays.
Discussion
The main finding of study 1 was that non-invasive ven-
tilation can significantly increase exercise tolerance in
patients with acute exacerbations of chronic respiratory
disease, reducing exercise desaturation. Exercise with
NIV was practical, safe and well tolerated without signif-
icant adverse events. The finding of study 2 however,
was that most patients admitted to hospital with non-
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Figure 1 Cycle endurance time at 20w increased with NIV support (p 0.04). n = 12 Horizontal bars represent mean values.
Table 2 Exercise parameters where workload held
constant (Study 1)
Without NIV With NIV P value
Tlim 184.4 (65.2) 331.1 (229.1) 0.04*
Resting SpO2 94.83 (2.17) 94.83 (2.55) 1.00*
Resting HR 94.33 (16.99) 93.83 (18.45) 0.86*
ΔSpO2 (%) -7.33 (5.12) -3.83 (4.90) 0.029
†
ΔHR (min-1) 16.33 (11.54) 16.33 (7.46) 0.93†
Borg dyspnoea 3.72 (1.90) 3.86 (1.87) 0.62†
Borg Leg discomfort 11.36 (2.29) 11.00 (2.86) 0.83†
All data presented as mean (SD) or median (range). Tlim, endurance time on
cycle ergometer at 20W; SpO2, oxygen saturation; HR, heart rate. Borg scores
were recorded at end of exercise. *paired t test, †Wilcoxon signed rank test.
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hypercapnic AECOPD are not likely to be eligible for an
NIV-assisted exercise intervention because their admis-
sion is too short, because they are too frail or have
other co morbidities or because they decline to
participate.
Efficacy of NIV assisted exercise
In study 1 we showed that patients unable to exercise
for five minutes at a low workload (20W) improved
their exercise performance when exercising with NIV.
As the tests were sequential and unblinded it is possible
that there was a learning effect or a placebo effect. The
fact that patients exercised for longer but to the same
level of reported symptoms supports the view that NIV
produced a genuine reduction in the work of breathing
consistent with previous reports [25-33]. A more com-
plex study design with patients exercising in random
order could have been adopted, however we wished in
particular in this pilot work to assess the feasibility of
NIV in the acute setting, establishing whether it was
possible to deliver this type of exercise intervention in
this group of patients at all. We adopted a sequential
approach, similar to that which might be adopted in
clinical practice - if patients could cycle at 20W unas-
sisted for five minutes then support would not be
Figure 2 Work done during cycle ergometry increased with NIV support (p = 0.016). Horizontal bar represents mean values.
Table 3 Screening for eligibility for study 2
n %
Met inclusion criteria 18 30%
Declined 10 56% of subtotal
Recruited 4 22% of subtotal
Other 4 22% of subtotal
Did not meet inclusion criteria 42 70%
Not fit to exercise 16 38% of subtotal
Poor prognosis 3 7% of subtotal
Expected stay < 24 hours 19 45% of subtotal
Other 4 10% of subtotal
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needed. An arbitrary time of five minutes cycling at 20
watts was used to define poor exercise capacity. We
wished to investigate the effect of NIV assisted exercise
in those with very limited exercise capacity as it is this
group in whom additional support for exercise is likely
to be most beneficial and thus where clinical resources
would be best concentrated.
Where NIV was employed patients were able to adapt
to using it quickly. A relatively low level of pressure
support (10 cmH2O) was sufficient to improve exercise
capacity consistent with previous work showing that
NIV with a mean inspiratory pressure of 11 cmH2O was
sufficient to improve walking distance in patients reco-
vering from acute on chronic respiratory failure [35]. It
remains to be established what the best strategy for aug-
menting exercise in this way is and we used two
approaches - maintaining a fixed workload to see if
endurance time increased or increasing the workload to
give a greater training stimulus. Both approaches
demonstrated that performance could be increased with
the assistance of NIV. It should be noted that 3 patients
displayed a reduction in the work done during exercise
while using NIV and the possibility that NIV might
impede rather than assist exercise in a given individual
needs to be considered. The performance characteristics
of the ventilator including trigger sensitivity, pressurisa-
tion rate and maximum flow capacity are important
issues to be considered when using NIV to augment
exercise as supporting ventilation in this context may be
more demanding than during sleep.
Feasibility of NIV assisted exercise during AECOPD
Study 1 was undertaken in patients admitted acutely to
a specialist respiratory hospital who were a younger
population with a range of chronic lung diseases and
fewer co-morbidities than the AECOPD group in study
2. Thus in study 2 only 30% of those admitted with an
acute exacerbation of COPD were suitable to approach
to discuss participation. The main reason for exclusion
was that 40% of patients were discharged from hospital
within 48 hours of admission reflecting a general reduc-
tion in length of stay [37] in the UK and increased evi-
dence for the effects of early supported discharge and
similar schemes [38]. A shorter length of stay, though
welcome, may have implications for assessing the impact
of interventions on patients admitted with AECOPD, as
the duration of treatment may make it difficult to estab-
lish whether there is an effect. This intervention may be
more appropriate for patients who remain an in-patient
for a longer period of time and future research studies
should consider this. We selected patients who did not
have a conventional clinical indication for NIV. Mena-
due et al recruited patients who were using NIV during
an acute admission with hypercapnic respiratory failure
due to AECOPD [35]. They found that NIV could
increase exercise capacity which suggests that exercise
with NIV in this patient population should be consid-
ered as an early strategy rather than waiting for patients
to no longer require NIV before this is begun.
The low proportion of patients suitable for NIV
assisted exercise has implications for trial design for stu-
dies with AECOPD with the low proportion of patients
actually eligible factored into power calculations and the
number of sites and duration of study required. For rou-
tine clinical practice, although NIV clearly can increase
exercise capacity even in acutely breathless patients,
many patients will decline to take part because they do
not believe that exercise is possible or desirable when
they are acutely unwell.
The main reason for declining to participate in the
study was that patients did not want to or believed
that they could not exercise. The correct balance
between “rest” and “mobilisation” in acute illness
needs to be defined and accepted by patients. This
could have implications in clinical practice as some
patients may choose not to participate in post exacer-
bation rehabilitation programmes with or without NIV.
Man et al found that approximately 40% of patients
assessed for eligibility for post-discharge pulmonary
rehabilitation were not randomised [20]. Additionally
this study required the patient to use an exercise bike.
This has the advantage of stability but may be unfami-
liar to some individuals. A different exercise strategy
such as walking with the NIV on a wheeled walker or
treadmill walking might have been more acceptable to
older patients [35,39].
A limitation of the study is that spirometry data were
not collected systematically for all patients admitted
with AECOPD to assess this aspect of disease severity
although the degree of exercise limitation caused by the
respiratory disease exacerbation is of course the main
issue and FEV1 is poorly predictive of exercise capacity
in COPD.
At present, pragmatic use of NIV to enhance mobili-
sation in patients with a clinical indication for it, in par-
ticular those who are weaning from ventilatory support
seems justified. If a more robust evidence base for the
effectiveness of NIV to augment exercise in AECOPD is
established then the case for its use could be made to
patients more strongly, which may increase compliance
beyond the levels observed in the present study.
Conclusion
Non-invasive ventilation can improve exercise tolerance,
with less desaturation in patients admitted to hospital
with an exacerbation of chronic respiratory disease. Our
experience suggests that it may be hard to recruit to
studies in older populations with AECOPD.
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